Physician profile
Sanjay Gupta
NPI 1538117999
$30,214.21
in general payments reported to CMS, 2019-2025
21 companies · $4,756 in 2025
The $4,756 reported for 2025 was more than what 82% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $2,803 · 2021: $9,600 · 2022: $4,783 · 2023: $3,680 · 2024: $3,540 · 2025: $4,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,130 · Food and Beverage: $2,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,130.35 |
| Food and Beverage | $2,845.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $17,417.49 | 2019-2025 | Tandem, Ri Hip Navigation, Pico |
| Stryker Corporation | $11,036.03 | 2019-2025 | Mako, Triathlon, Insignia |
| Boston Scientific Corporation | $560.61 | 2019-2023 | |
| Nevro Corp. | $321.36 | 2023-2024 | Senza |
| Amgen INC. | $216.98 | 2023-2025 | Prolia, Evenity, Prolia |
| Davol INC. | $179.96 | 2024 | Arista Ah Flexitip |
| Depuy Synthes Sales INC. | $75.62 | 2021-2022 | |
| Fx Shoulder Solutions, INC | $70.29 | 2021 | |
| Zimvie INC. | $48.22 | 2023 | |
| Bioventus LLC | $37.15 | 2021-2025 | Gelsyn-3 |
| Ferring Pharmaceuticals INC. | $36.80 | 2025 | Euflexxa |
| Saluda Medical Americas, INC. | $34.16 | 2025 | Evoke |
| Vertex Pharmaceuticals Incorporated | $33.98 | 2025 | |
| Abbott Laboratories | $29.59 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $26.33 | 2024 | Exparel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $24.44 | 2021 | |
| Fidia Pharma USA INC. | $20.05 | 2023 | Triluron, Hymovis |
| Globus Medical, INC. | $19.95 | 2025 | Senza |
| Medartis INC. | $13.74 | 2021 | |
| Medtronic, INC. | $11.46 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,296.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.